For children over 12 months of age, there were 4 cases of inpatient pneumonia in children who had received the 12 month PPV-23 compared with 7 cases in those that had not during the same follow up period. There were no cases of IPD throughout the study period. This study has shown that 1, 2, or 3 doses of PCV-7 in infancy primed infants sufficiently elicit an excellent booster response to the PPV-23 at 12 months ATM Kinase Inhibitor concentration of age for all PCV-7 serotypes. Furthermore, there were good antibody responses to the 16 non-PCV-7
serotypes following PPV-23 at 12 months. The antibody concentrations for all 23 serotypes remained significantly higher at 17 months of age in the PPV-23 group compared to the group that had not received PPV-23. In addition, this study has shown that priming with a single PCV-7 dose in infancy produced the greatest booster (memory) response for most serotypes following PPV-23 at 12 months compared with 2 or 3 PCV-7 doses. Responses following the PPV-23 were similar for those children that had received either 2 or 3 PCV-7 doses in infancy and lower than that in children
who received a single PCV-7 dose. The immunological explanation for the single PCV-7 dose having a better booster response is not clear. Post booster antibody concentrations are this website usually higher in those that have had a stronger primary response [34]. One study found that a stronger primary response was more likely following higher doses of antigen and/or a higher concentration of carrier protein, possibly through the enhanced induction of antibody producing plasma cells [35]. However this would not explain the findings in our study of a better booster response in the single dose group as our previously published data has shown that a single PCV-7 dose (lower antigen dose) administered at 14 weeks of age induced a weaker primary Adenosine response [29]. In that previous study, a significant immunological response was found in the single dose group compared with an unvaccinated control group, but significantly lower
GMC for all PCV-7 serotypes compared to 2 or 3 PCV-7 doses [29]. Another possible explanation for the better booster response in the single PCV-7 dose group may be that a single antigen challenge rather than multiple antigen exposures, may preferentially drive the induction of memory B cells (which are required for a booster response), rather than plasma cells [36]. Having a greater pool of memory B cells would subsequently elicit a greater booster response. A fewer dose (single PCV-7 dose) primary series may preferentially induce B cell differentiation away from plasma cells, towards memory B cells compared to repeated antigen exposure associated with 2 or 3 PCV-7 dose primary series [8] and [11].